A 45-year-old woman undergoes surgery for advanced ovarian cancer (Stage IIIC). Her surgeon achieves optimal cytoreduction with residual disease <1 cm. According to FIGO staging and current oncology practice, which combination of chemotherapy best demonstrates benefit in the ICON7 and GOG-0218 trials?
- A Carboplatin + paclitaxel alone for 6 cycles
- B Cisplatin + cyclophosphamide alone
- C Carboplatin + docetaxel + bevacizumab
- D Carboplatin + paclitaxel + bevacizumab (concurrent and maintenance) ✓
Explanation
Both ICON7 (carboplatin + paclitaxel ± bevacizumab) and GOG-0218 (carboplatin + paclitaxel ± bevacizumab) demonstrated that adding bevacizumab (anti-VEGF monoclonal antibody) concurrently with chemotherapy and as maintenance therapy significantly prolonged progression-free survival in advanced ovarian cancer, particularly in high-risk Stage IIIC–IV disease or suboptimally debulked disease. Carboplatin replaced cisplatin due to a better tolerability profile. The standard backbone remains carboplatin + paclitaxel, with bevacizumab added in high-risk patients per current ESMO/FIGO guidance.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.